Transcranial Magnetic Stimulation Offers Hope for Treatment-Resistant Depression in Chilean Youth

In Chile, the numbers arrive like a diagnosis: three out of every four young people carry symptoms of anxiety or depression. The country ranks second among OECD nations in adolescent suicide rates. According to the government's most recent longitudinal survey of early childhood development, more than a quarter of Chilean teenagers—26.5 percent—show moderate to severe manifestations of these conditions, a figure the government itself has flagged as cause for serious concern. The Ministry of Health reports that suicide remains among the leading causes of death for people aged 15 to 29, a rate that exceeds the global average tracked by the World Health Organization. In nine out of ten cases, mental illness is the underlying factor.

Javier's daughter Emilia is sixteen. She has always been emotionally sensitive, he explains—a trait that sent her to psychologists throughout childhood and into a series of psychiatric treatments that never quite landed. As adolescence arrived, depression took hold. Medications came next, but Emilia grew resistant to them, her mood volatile and reactive. Javier's account is not unusual. Across the country, parents describe the same exhausting cycle: trying therapy after therapy, medication after medication, watching their children's pain persist while doors close one after another. They speak of desperation—the daily weight of holding up someone whose suffering will not budge.

Between one quarter and two fifths of adolescents with depression fail to respond to standard initial treatments: antidepressants, psychotherapy, or both. Doctors call this treatment-resistant depression. According to María José Arroyo, a child and adolescent psychiatrist at Brain Treatment Center Chile, the clinical definition is precise: a teenager who has carried depressive symptoms for more than a year and has completed at least two different medication regimens, each lasting six to eight weeks or longer, without meaningful improvement. Normally, antidepressants begin to show effect within two to three weeks. The process moves slowly because doctors start with lower doses, but change should be visible—in how the person functions socially, in their ability to engage with others, in shifts in sleep and appetite and energy. When none of that happens, the diagnosis becomes clear.

When medication and talk therapy fail, the risk of suicidal thinking rises sharply. This is where transcranial magnetic stimulation enters the picture. The technique is non-invasive and painless. A electromagnetic coil placed against the scalp generates a magnetic field strong enough to penetrate two centimeters into the brain's outer layer, where it modulates the activity of neural circuits involved in mood regulation. The FDA has approved it for treatment-resistant depression in patients as young as fifteen. The number of sessions is determined after an initial evaluation. Arroyo notes that roughly forty percent of depressed adolescents do not respond to medication, and those drugs often carry unwanted side effects. Transcranial magnetic stimulation eliminates those secondary effects while giving seventy percent of patients a brain that will actually respond to treatment.

Emilia underwent the therapy. The change came quickly—faster than anything the family had found in years of searching. Where she had been deeply depressed and unmotivated, unreachable even to those trying hardest to reach her, she began to shift. The pharmaceutical treatments had not served her well, Javier says, but this did. Within weeks, his daughter was the one waking first in the morning, ready and eager. Her concentration sharpened. Her mood lifted. The family recovered moments together that had seemed lost. It was, he says, very moving.

Clinical evidence published in the journal Clinical Neurophysiology documents what families like Emilia's have experienced. In the patient population studied, depression went into remission in forty-one percent of cases. Anxiety remitted in one out of every three adolescents. Most strikingly, suicidal ideation—active thoughts of self-harm—disappeared in more than sixty percent of those who had been experiencing such thoughts. Some of these improvements appeared within the first week of treatment. For families who have watched their children suffer through failed medication after failed medication, who have felt the particular helplessness of standard psychiatry reaching its limits, the therapy represents something that had seemed impossible: a door that actually opens.